CN105273063B - Adjust polypeptide and its application of FGFR1 activity - Google Patents
Adjust polypeptide and its application of FGFR1 activity Download PDFInfo
- Publication number
- CN105273063B CN105273063B CN201510855734.2A CN201510855734A CN105273063B CN 105273063 B CN105273063 B CN 105273063B CN 201510855734 A CN201510855734 A CN 201510855734A CN 105273063 B CN105273063 B CN 105273063B
- Authority
- CN
- China
- Prior art keywords
- fgfr1
- activity
- polypeptide
- bacteriophage
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of polypeptide R1 P1 for adjusting FGFR1 (fibroblast growth factor acceptor 1) activity, it can specifically bind with FGFR1, and there is apparent adjustment effect to its activity, the activity of p ERK in FGFR1 major downstream signal paths MAPK can be significantly inhibited, energy conspicuousness after R1 P1 peptide joint cavity injection DMM model mices is reduced into cartilage degeneration and matrix loss is horizontal, delays arthritic processes.And the polypeptide has the advantages that molecular weight is small, it is simple to prepare, quality controllable, immunogenicity is low etc., can prepare alleviation or treatment medicine for treating arthritis, there is good potential using value.
Description
Technical field
The invention belongs to biotechnologies, and in particular to it is a kind of adjust FGFR1 activity polypeptide R1-P1 and its making
It is standby to alleviate or treat the application in Osteoarthritis disease medicament.
Background technology
Osteoarthritis (osteoarthritis, OA) is articular cartilage degeneration, denaturation and secondary cartilage proliferation, is ossify
It is to seriously affect its people using arthralgia, movable function obstacle as a kind of disease of main clinical manifestation for main pathological change
The great public health problem of Health and Living quality.Articular cartilage damage regression at present there is no effective medicine, clinical
On mainly carry out nutrition lubricating joint using Sodium Hyaluronate and Glucosamine so as to alleviate symptom, however can not fundamentally press down
The process of cartilage degeneration processed.Arthritis development often takes arthroscopic Radical dissection and joint replacement surgery to the later stage.However
Either drug therapy or operative treatment, there are it is different degrees of the defects of, the medical demand of patient can not be met.Therefore,
There is an urgent need to develop the medicine of new joint injury regression.
The screening of drug target at present is concentrated mainly on cell-membrane receptor and is metabolized relevant enzyme, such as IL-1 receptors, preceding
Row parathyrine E2 synthase (PGES), TNF-α, Bmp7 etc..FGFR (fibroblast growth factor acceptor) is a kind of with itself phosphorus
The transmembrane tyrosine kinase receptor of souring activity combines with its respective ligand FGFs (fibroblast growth factor) and adjusts cell
Proliferation, differentiation, migration and survival etc. play a significant role during histoorgan development and injury repair.Have now been found that 4
Kind FGFR, i.e. FGFR1, FGFR2, FGFR3 and FGFR4.It is special that research group utilizes tamoxifen to can induce articular cartilage early period
Property knock out FGFR1 mouse models, by analyze 3 kinds of arthritis models (aging model, antigen induction arthritis model
Joint instability model (the Destabilization of of (Antigen-induced Arthritis, AIA), wound-induced
The Medial Meniscus, DMM)) joint pathology and Quantitative marking, as a result show articular chondrocytes knock out FGFR1 energy
The loss of articular cartilage matrix proteoglycan PGs caused by enough anti-aging, AIA models simultaneously mitigates joint caused by DMM models
Cartilage structure destroys.FGFR3 expression raising, MMP-13 expression declines may be the potential machine that FGFR1 knocks out Saving cortilage cartilage
System.The studies above result prompting targeted inhibition FGFR-1 may be alleviation or treatment articular cartilage damage and the new strategy of regression.
Therefore, using FGFR1 as target spot is intervened, FGFR1 specific bond polypeptides are screened, it is studied and is alleviating or treating Osteoarthritis disease
In function, be a kind of feasible thinking.
Invention content
In view of this, the purpose of the present invention is to provide it is a kind of adjust FGFR1 activity polypeptide, with molecular weight it is small,
Prepare the advantages such as simple, quality controllable, immunogenicity is low；The present invention also provides it to prepare alleviation or treatment Osteoarthritis
Application in disease medicament.
The technical solution that the present invention takes is as follows：
1st, the polypeptide R1-P1, amino acid sequence Gly-Pro-Pro-Asp-Trp-His-Trp- of FGFR1 activity are adjusted
Lys-Ala-Met-Thr-His。
2nd, the polypeptide R1-P1 of above-mentioned adjusting FGFR1 activity is preparing the application in alleviating or treating medicine for treating arthritis.
The beneficial effects of the present invention are：R1-P1 polypeptides provided by the invention can with FGFR1 specific bonds, and should
Polypeptide has the advantages that molecular weight is small, it is simple to prepare, quality controllable, immunogenicity is low etc.；In addition, the present invention is by establishing mouse knee
Arthritis model simultaneously injects the discovery of R1-P1 peptides, and R1-P1 peptides can delay the arthritic processes of DMM model mices, it is prompted to make
It is standby to alleviate or treat in medicine for treating arthritis with good application value.
Description of the drawings
In order to make the purpose of the present invention, technical solution and advantageous effect clearer, the present invention provides drawings described below：
Fig. 1 is that ELISA method verifies R1-P1 peptides and the combination situation of FGFR1.
Fig. 2 is that chemical-activated luciferase gene expression detects shadow of 10 μM of R1-P1 peptides to FGFR1 downstream signals p-ERK levels
It rings, * * are represented and blank control group ratio, P<0.01；* * are represented and blank control group ratio, P<0.001.
Fig. 3 examines 10 μM of R1-P1 peptides to p-ERK in FGFR1 major downstream signal paths MAPK for Western blot methods
It influences；Wherein, 1 swimming lane is blank control group, and 2 swimming lanes are PD166866 inhibitor groups, and 3 swimming lanes are R1-P1 peptide groups.
Fig. 4 is the fast green coloration result of DMM model mice knee joint histotomy safranine.
Fig. 5 loses appraisal result for DMM model mice knee joint histotomies articular cartilage matrix.
Fig. 6 is DMM model mice knee joint histotomy cartilage degeneration appraisal results.
Specific embodiment
The preferred embodiment of the present invention is described in detail below.The experiment side of actual conditions is not specified in embodiment
Method, usually according to normal condition or according to the normal condition proposed by manufacturer.
FGFR1, the anti-FGFR1 antibody of mouse used in preferred embodiment is purchased from Sigma Co., USA, 12 peptide library of bacteriophage
Screening reagent box (including ER2738 strains) is purchased from New England Lab companies of the U.S., and pcDNA3.1-Myc empty carriers are by this
Seminar preserves, and Myc-FGFR1 plasmids are given by Washington, DC university David professors Ornitz.
Embodiment 1, the polypeptide that elutriation can be specifically bound with FGFR1 from 12 peptide library of bacteriophage
1st, the elutriation in 12 peptide library of bacteriophage
FGFR1 solution with a concentration of 20 μ g/mL (is molten by 8.6 sodium bicarbonate solution of a concentration of 0.1mol/L, pH
Agent) 150 μ L coated elisa plates, 4 DEG C are coated with overnight, discard coating buffer, and full hole adds in the BSA solution of a concentration of 5mg/mL (with dense
It is solvent to spend for 0.1mol/L, pH sodium bicarbonate solution for being 8.6), 37 DEG C of closing 1h discard confining liquid, (are contained with TBST
The TBS buffer solutions of Tween-20, a concentration of 1mL/L of Tween-20 during first round elutriation, when the second wheel and third round elutriation
The concentration of Tween-20 is improved to 5mL/L) it washs 6 times, input bacteriophage (puts into 12 peptide library stoste of bacteriophage during first round elutriation
With the mixed liquor of TBST, the second wheel and the bacteriophage of specific binding that input previous round elutriation goes out during third round elutriation), room temperature
Lower mild concussion is incubated 1h, discards the bacteriophage of non-specific binding, is washed 10 times with TBST, add in a concentration of 0.2mol/L,
PH is 2.2 glycine-HCI buffer solution, and the bacteriophage that mildly concussion 8min elutions are specifically bound at room temperature draws elution
Liquid adds in the 150 μ L of Tris-HCl buffer solutions that a concentration of 1mol/L, pH are 9.1 and neutralizes, measures titre, spare；
ER2738 bacterium are seeded in LB culture mediums 20mL, (OD600 values are about to mid-log phase for 37 DEG C of violent shake cultures
0.5), add in it is aforementioned neutralized with Tris-HCl buffer solutions after bacteriophage elution liquid 100 μ L, 37 DEG C of shake culture 4.5h, 4 DEG C,
Rotating speed 10000rpm centrifuges 10min, draws the supernatant containing bacteriophage, adds in the PEG/ for being equivalent to 1/6 volume of supernatant
NaCl solution (is made of, similarly hereinafter) the NaCl of the PEG8000 and a concentration of 2.5mol/L of a concentration of 200g/L, and 4 DEG C stand overnight
Precipitating phage, 4 DEG C, rotating speed 10000rpm centrifugation 15min, abandon supernatant, with TBS buffer solutions be resuspended phages, then from
The heart takes supernatant, adds in the PEG/NaCl solution for being equivalent to 1/6 volume of supernatant, ice bath precipitating phage 90min, and centrifugation is abandoned
Clear liquid is resuspended phages, then centrifuging and taking supernatant with the TBS buffer solutions 1mL of the Sodium azide containing a concentration of 0.2g/L, adds
Enter to be equivalent to the PEG/NaCl solution of 1/6 volume of supernatant, ice bath precipitating phage 90min, supernatant is abandoned in centrifugation, with containing dense
Phages, then centrifuging and taking supernatant is resuspended in the 200 μ L of TBS buffer solutions for spending the Sodium azide for 0.2g/L, measures titre, as
The input bacteriophage of next round elutriation；
Repeat the above steps common progress three-wheel elutriation, the bacteriophage that enrichment can be specifically bound with FGFR1；Third round elutriation
The bacteriophage gone out is no longer expanded with ER2738 bacterium.
The bacteriophage rate of recovery of each wheel elutriation is shown in Table 1.
Table 1. respectively takes turns the rate of recovery of panning process pnagus medius
| Round | Put into bacteriophage (pfu) | Recycle bacteriophage (pfu) | The rate of recovery (%) |
| 1 | 1×1011 | 1×103 | 1×10-8 |
| 2 | 4.14×1011 | 3.98×105 | 9.6×10-7 |
| 3 | 6.7×1011 | 3.7×106 | 5.52×10-6 |
As shown in Table 1, after three-wheel elutriation, gradually increase with the rate of recovery of the bacteriophage of FGFR1 specific bindings, table
It is bright with FGFR1 to there is the bacteriophage compared with high-affinity to be effectively enriched with.
2nd, the DNA extractions and sequencing of bacteriophage
ER2738 bacterium are seeded in LB culture mediums, 37 DEG C of violent shake cultures to mid-log phase, divide and 1mL is taken to put culture tube
In, the bacteriophage monoclonal of the random picking from the titer determination tablet for the bacteriophage that third round elutriation goes out is added in, 37 DEG C are acutely
Shake culture 4.5h, centrifugation take the 500 μ L of supernatant containing bacteriophage, add in 200 μ L of PEG/NaCl solution, and precipitation at room temperature is bitten
Supernatant is abandoned in thalline 10min, centrifugation, adds in 100 μ L of iodide buffer solution and phages are resuspended, add 250 μ L of ethyl alcohol, room
Temperature incubation 10min precipitates phage DNA and most of phage proteins retain in the solution, and supernatant, DNA precipitations are abandoned in centrifugation
It is washed, is resuspended in after vacuum drying in 30 μ L of TE buffer solutions with the ethyl alcohol of a concentration of 700mL/L.5 μ L of the solution are taken, entrust Shanghai
Jia Gen bio tech ltd is sequenced.
The present embodiment as stated above from the bacteriophage that third round elutriation goes out random 23 bacteriophage monoclonals of picking into
Row DNA is extracted and sequencing, and screening obtains 3 kinds of 12 peptides with FGFR1 with higher affinity, it is highest more to select wherein repetitive rate
Peptide R1-P1 (amino acid sequence is as shown in SEQ ID No.1) is studied, as a result, it has been found that R1-P1 peptides can be specifically bound
FGFR1。
Embodiment 2, the artificial synthesized polypeptide that can be specifically bound with FGFR1
According to the amino acid sequence of R1-P1 peptides, commission Shanghai Qiangyao Biotechnology Co., Ltd. uses standard Fmoc schemes
Synthesis in solid state R1-P1 peptides.After measured, synthesis polypeptide purity is higher than 95%, -70 DEG C of preservations of temperature.
The combination of embodiment 3, ELISA method verification synthesis polypeptide and FGFR1
In 96 hole elisa Plates, 20 μ L of R1-P1 peptide solutions and coating buffer solution that a concentration of 1mmol/ μ L are added in per hole (take
Sodium carbonate 0.3g, sodium bicarbonate 0.58g and Sodium azide 0.04g, are dissolved in water, and adjust pH to 9.6, add water and be diluted to 200mL,
Up to) 80 μ L, while blank control group (being added without R1-P1 peptides) is set, 4 DEG C of coatings overnight, discard solution, and full hole adds in concentration
For the calf serum solution (using the PBS that pH is 7.4 as solvent) of 50g/L, 37 DEG C of closing 60min discard solution, (are contained with PBST
Have the PBS of the Tween-20 of a concentration of 0.5mL/L, pH 7.4) it washs 3 times, add in the FGFR1 solution of a concentration of 100 μ g/mL
The 70 μ L of PBS that 30 μ L and pH are 7.4,37 DEG C are incubated 1h, are washed 3 times with PBST, add in 1:The 500 diluted anti-FGFR1 antibody of mouse
(the BSA solution for being 1% using mass percentage concentration is retarder thinner) 100 μ L, 37 DEG C are incubated 1h, discard solution, 5 are washed with PBST
It is secondary, the 100 μ L of rabbit anti-mouse igg of HRP labels are added in, 37 DEG C are incubated 30min, discard solution, are washed 5 times with PBST, add in tetramethyl
100 μ L of base benzidine-hydrogen peroxide urea solution, 37 DEG C are protected from light colour developing 10min, add in the sulfuric acid solution of a concentration of 2mol/L
Reaction is terminated, OD450 values are measured at wavelength 450nm, are as a result represented with the mean value of 3 multiple holes.The results are shown in Figure 1, R1-P1
Peptide has higher Percentage bound with FGFR1.
Embodiment 4, synthesis polypeptide detect the adjustment effect of FGFR1 activity
1st, activation of the chemical-activated luciferase gene expression detection synthesis polypeptide to FGFR1 major downstream signal paths MAPK
Before transfection for 24 hours, it by 293T cell inoculations to 12 well culture plates, after length to 80% fusion, is transfected with efficient eukaryon
Reagent VigoFect transfects 0.1ng Myc-FGFR1 plasmids (being compared with pcDNA3.1-Myc plasmids) and ERK access reports simultaneously
Gene plasmid (50ng PFR-luc, 50ng P-EIK-1 and 5ng internal reference PRL-TK) is accused, liquid is changed after 3h, adds in 10 μM afterwards for 24 hours
The processing of R1-P1 peptides, while blank control group (being added without R1-P1 peptides) and PD166866 control groups are set (with FGF inhibitor
PD166866 substitutes R1-P1 peptides), processing discards culture medium afterwards for 24 hours, rinses cell 2 times with 1 × PBS of precooling, is added in per hole
300 μ L 1 × Universal Lysis Buffer (ULB) put -80 DEG C of low temperature refrigerator frost cracking 1h, then the oscillation of room temperature vortex
30min is cracked completely to cell, measures uciferase activity, record firefly luciferase flat light emission (Rlus1) and sea pansy
Luciferase flat light emission (Rlus2), the transcription relative activity value using the relative ratio of Rlus1/Rlus2 as reporter gene,
As a result it is represented with the means standard deviation of 3 multiple holes.The results are shown in Figure 2, and 10 μM of R1-P1 peptides can be significantly inhibited under FGFR1
The activity of p-ERK is swum, R1-P1 peptides is prompted to may be by adjusting the activity of p-ERK to adjust the physiology course of cell.
2nd, Western blot methods detect synthesis polypeptide R1-P1 to p-ERK in FGFR1 major downstream signal paths MAPK
Activation
Before transfection for 24 hours, it by 293T cell inoculations to 35mm culture dishes, after length to 80% fusion, is transfected with efficient eukaryon
Reagent VigoFect transfects 0.1ng Myc-FGFR1 plasmids (being compared with pcDNA3.1-Myc plasmids) simultaneously, and liquid is changed after 3h,
It adds in 10 μM of R1-P1 peptides processing afterwards for 24 hours, while blank control group (being added without R1-P1 peptides) and PD166866 control groups is set
(substituting R1-P1 peptides with FGF inhibitor PD166866), processing for 24 hours, collects cell, and lytic cell is blown and beaten with cell pyrolysis liquid, in
Cell homogenates liquid, Ultrasonic Cell Disruptor smudge cells (parameter setting are collected on ice：Amplification factor 35%, total time 20s, each 5s,
It is spaced 3s).Protein sample adds in isometric 2 × SDS-PAGE loading buffer sample-loading buffers, boils 5min, room
SDS-PAGE is carried out after temperature cooling, and (using the concentration glue of a concentration of 50g/L, the separation gel of a concentration of 90g/L, electrophoretic parameters are
80V 20min, 120V 80min), after electrophoresis, albumen electricity is transferred on (constant current 3000mA 60min) to pvdf membrane, is used
8% skimmed milk power TBST (Tris-HCl containing 20mM, 137mM NaCl, 0.1%Tween-20) closes 1h in 37 DEG C of shaking tables, then
Add in 1:The 1000 diluted anti-FGFR1 primary antibodies of mouse, 4 DEG C overnight, discard solution, are washed 5 times with TBST, add in the rabbit of HRP labels
Anti- mouse secondary antibody, 37 DEG C of incubation 1h, discards solution, is washed 5 times with TBST, ECL chemical luminescence for liquid (Pierce companies of the U.S., A, B liquid
1:1 mixing) it exposes, development.The results are shown in Figure 3, and compared with the control group, PD166866 inhibitor group completely inhibits the phosphorus of ERK
Acidification is horizontal, and the phosphorylation level conspicuousness of R1-P1 peptide groups ERK reduces, and shows that R1-P1 peptides can significantly inhibit FGFR1 downstreams
The activity of p-ERK.
The influence of embodiment 5, synthesis polypeptide to mouse gonitis model
1st, unstable (Destabilization of the medial meniscus, the DMM) model of medial meniscus is built
It is vertical
DMM operation structure mouse knee joint endoprosthesis inflammation models are implemented using microsurgery.Operation is divided into DMM operation groups
With sham-operation Sham groups, each group sets control group respectively.Key step of performing the operation is as follows：DMM operations group for mouse anesthesia is fixed,
After disinfection, right side of mice knee joint is opened, blunt separation soft tissue cuts off medial meniscus platform ligament, band with microinstrument
Line sewing needle sutures capsular ligament, closes articular cavity, last skin suture；Sham-operation Sham groups only open right side of mice knee pass
Section, blunt separation soft tissue do not cut off medial meniscus platform ligament, skin suture.Pay attention to avoiding damage to articular cartilage in art,
It is postoperative to be not fixed operating limb, freely activity in cage, intraperitoneal injection penicillin prevention infection.
2nd, intraarticular injection R1-P1 peptides
1 week DMM operations group and sham-operation Sham groups are each respectively to intraarticular injection R1-P1 peptides after DMM model surgeries
From control group then injecting normal saline, weekly, continuous 8 weeks, finally draw materials simultaneously.
It is as follows to inject specific method：R1-P1 peptides are diluted to 1 μ g/ μ L (1mM mother liquors) with physiological saline, by mouse anesthesia
After fixed, disinfection, with skin at micro- blade cut knee joint, exposure articular cavity, according to the 10 μ LR1-P1 of measurement of 10 μ g/ only
Peptide dilution is injected in articular cavity, while in the same manner to 10 μ L physiology salts of control group mice intraarticular injection
Water, once a week, continuous 8 weeks.
3rd, articular cartilage damage regression pathological score
Mouse joint materials after, 4%PFA is fixed, formic acid (quick decalcifying Fluid) decalcification, specimens paraffin embedding slices.Mouse joint
Slice there are two types of mode, i.e. coronal cut is cut with sagittal, herein in a manner that sagittal is cut.From medial meniscus during sagittal slices
Start to be sliced, be spaced corresponding position fishing piece, ensure to drag for piece between each individual in same position as possible, 4 sample/pieces,
About 25 slice, thin pieces (soft tissue occurs in articular surface, represents to have arrived at the final position of slice).Each sample interval selection is similary
The slice, thin piece 10 of position is opened, and progress safranin O-(safranin O can make proteoglycans dye red, fast green to make mineralised zones for fast green dyeing
Dye green), it is taken pictures by IPP softwares, carry out cartilage degeneration scoring using arthritis score standard comments with matrix loss
Point (slice, thin piece for choosing regression most serious in entire joint scores, and at least two people carry out double blind scoring, this two kinds scoring
Method is that higher to represent arthritic lesions regression more serious for score value), specific standards of grading are shown in Table 2 and table 3；With blank control group
It compares, * P<0.05, * * P<0.001.
2 cartilage degeneration of table scores
| 0 point | Articular cartilage is complete |
| 0.5 point | Safranine dyeing is lost but is changed without structure |
| 1 point | Superficial layer fibrillation but without cartilage lose |
| 2 points | The vertical fracture of superficial layer, and there is loss in joint superficial face |
| 3 points | Reach the vertical fracture or destruction of joint of calcified cartilage, and range<25% articular surface |
| 4 points | The vertical fracture or destruction of joint of calcified cartilage are reached, and range is in articular surface 25%-50% |
| 5 points | The vertical fracture or destruction of joint of calcified cartilage are reached, and range is in articular surface 50%-75% |
| 6 points | Reach the vertical fracture or destruction of joint of calcified cartilage, and range>75% articular surface |
3 matrix of table loses scoring
| 0 point | Non- mineralising cartilage normal coloring |
| 1 point | There is the reduction dyed in the 1-100% of articular surface, but does not occur dyeing complete loss |
| 2 points | Non- mineralising cartilage dyeing is lost completely, is lost area and is less than articular surface 25% |
| 3 points | Non- mineralising cartilage dyeing is lost completely, loses area in articular surface 25%-50% |
| 4 points | Non- mineralising cartilage dyeing is lost completely, loses area in articular surface 50%-75% |
| 5 points | Non- mineralising cartilage dyeing is lost completely, is lost area and is more than articular surface 75% |
Safranine is fast green to dye and scores statistical result as shown in Figure 4,5, 6, compared to the control group of injecting normal saline, DMM
The mouse cartilage degeneration of R1-P1 peptides is injected after operation and matrix is lost degree conspicuousness and reduced, shows that R1-P1 peptides can prolong
The arthritic processes of slow DMM model mices.
Finally illustrate, preferred embodiment above is merely illustrative of the technical solution of the present invention and unrestricted, although logical
It crosses above preferred embodiment the present invention is described in detail, however, those skilled in the art should understand that, can be
Various changes are made to it in form and in details, without departing from claims of the present invention limited range.
Claims (2)
1. adjust the polypeptide R1-P1 of FGFR1 activity, which is characterized in that amino acid sequence Gly-Pro-Pro-Asp-Trp-
His-Trp-Lys-Ala-Met-Thr-His。
2. the polypeptide R1-P1 of FGFR1 activity is adjusted described in claim 1 in alleviation or treatment medicine for treating arthritis is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510855734.2A CN105273063B (en) | 2015-11-30 | 2015-11-30 | Adjust polypeptide and its application of FGFR1 activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510855734.2A CN105273063B (en) | 2015-11-30 | 2015-11-30 | Adjust polypeptide and its application of FGFR1 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105273063A CN105273063A (en) | 2016-01-27 |
| CN105273063B true CN105273063B (en) | 2018-06-12 |
Family
ID=55142956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510855734.2A Active CN105273063B (en) | 2015-11-30 | 2015-11-30 | Adjust polypeptide and its application of FGFR1 activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105273063B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106543270B (en) * | 2016-12-06 | 2019-11-19 | 中国人民解放军第三军医大学第三附属医院 | Adjust the active polypeptide of FGFR1 and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1246926A2 (en) * | 2000-01-12 | 2002-10-09 | The Mount Sinai School of Medicine of New York University | Methods of identifying modulators of the fgf receptor |
| CN101585866A (en) * | 2009-07-02 | 2009-11-25 | 中国人民解放军第三军医大学野战外科研究所 | Polypeptide for regulating activity of FGFR3 and screening method and application thereof |
| WO2012158704A1 (en) * | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
-
2015
- 2015-11-30 CN CN201510855734.2A patent/CN105273063B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1246926A2 (en) * | 2000-01-12 | 2002-10-09 | The Mount Sinai School of Medicine of New York University | Methods of identifying modulators of the fgf receptor |
| CN101585866A (en) * | 2009-07-02 | 2009-11-25 | 中国人民解放军第三军医大学野战外科研究所 | Polypeptide for regulating activity of FGFR3 and screening method and application thereof |
| WO2012158704A1 (en) * | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
Non-Patent Citations (1)
| Title |
|---|
| 噬菌体展示技术筛选bFGF模拟短肽;黄慧贤等;《中国生物工程杂志》;20060525;第26卷(第05期);第7-10页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105273063A (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pascual-Garrido et al. | Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5‐year‐followup | |
| CN105168251A (en) | Stem cell preparation as well as preparation method and application thereof | |
| Magarian et al. | Human anterior cruciate ligament fibroblasts from immature patients have a stronger in vitro response to platelet concentrates than those from mature individuals | |
| AU2019317696A1 (en) | Method and composition for promoting cell growth and tissue repair | |
| CN107841491A (en) | A kind of expression for increasing thyroid peroxidase expression quantity | |
| CN105273063B (en) | Adjust polypeptide and its application of FGFR1 activity | |
| CN105255887A (en) | Recombinant lentivirus and its use in preparation of drug for treating cocaine addiction | |
| Liu et al. | Intestinal organoids and organoids extracellular vesicles for inflammatory bowel disease treatment | |
| Choi et al. | Disorganization of the facial nucleus after nerve lesioning and regeneration in the rat: effects of transplanting candidate reparative cells to the site of injury | |
| Wei et al. | Acellular nerve xenografts based on supercritical extraction technology for repairing long-distance sciatic nerve defects in rats | |
| Zhang et al. | Transplantation of olfactory ensheathing cells combined with chitosan down-regulates the expression of P2X7 receptor in the spinal cord and inhibits neuropathic pain | |
| CN103724410A (en) | Fusion proteins for regulating and controlling CCR5 and CXCR4 genes and regulation and control method | |
| CN106693055A (en) | Cerebellar decellularized regeneration biological scaffold, preparation method and application thereof | |
| EP3834834A1 (en) | Drug used for treating tissue necrosis or for improving cardiac function | |
| CN108721311A (en) | Astragaloside is preparing the application in promoting the regenerated drug of neural stem cell | |
| CN107250348A (en) | Developed using expression LGR4, LGR5 and LGR6 epithelial stem cell in organizations and using the method for the micro- aggregation body unit of least polar functioning cell | |
| WO2022227289A1 (en) | Method for detecting sensitivity of organoid to macromolecular drug with sandwich culture system | |
| CN105963686A (en) | Application of collagen peptide in preparing medicine for preventing or treating osteoporosis | |
| CN108148901A (en) | Applications of the TFEB as cerebral apoplexy biomarker and therapy target | |
| CN104740628B (en) | CTGF chimeric and its application for treating liver fibrosis | |
| US20190321411A1 (en) | Method for promoting bioactive factors in placenta tissue and product thereof | |
| Xiao et al. | Effects of drug serum of anti-fibrosis I herbal compound on calcium in hepatic stellate cell and its molecular mechanism | |
| CN108337893A (en) | Slow virus carrier and the application of a kind of sgRNA and its structure | |
| CN107854730A (en) | It is crosslinked the preparation method and applications of CGA sodium alginate gelatin cross-blend syndesis sticking patch | |
| CN105131087B (en) | There is vibrio mimicus OmpU adhesin protein binding peptide, peptide composition and the application thereof of Antagonism activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |